An interventional study of Decision Aid and Questionnaire Administration in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 and Anatomic Stage IB Breast Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.
Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 142nd largest by planned enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 65 with no phase, reaches primary completion later than 41 of the 50 other live ones, and was the 139th registered.
287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.
Browse Carcinoma, Intraductal, Noninfiltrating studies →31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:
Providence Health & Services · Sites in United States
Ages 18+
HeroSupport SA · Sites in United States
Ages 40+ · Women only
University of Florida · Sites in United States
Ages 18+
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 1991; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.
Median enrollment 51 across the 171 interventional studies, 109 across the 38 observational. Of the 140 that completed or were terminated, 59 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 210 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 9 studies filed under Carcinoma, Intraductal, Noninfiltrating — fewer than ten, so there is no comparison to draw.
15 of the studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04722692Phase 3Uppsala UniversityDelayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ | 2026-12-30 |
| NCT03546972M.D. Anderson Cancer CenterDiabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants | 2026-11-30 |
| NCT03909282Stanford UniversitySurgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma | 2026-12 |
| NCT03448926PreludeDxThe PREDICT Registry: | 2026-12 |
| NCT05340673City of Hope Medical CenterComparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer | 2026-12-15 |
Add all 15 to your calendar (.ics) → With an account.
Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial studies the acceptability and how well decision making tool works in supporting decision making in contralateral prophylactic mastectomy in patients with newly diagnosed breast cancer. Decision making tool may help patients with early stage breast cancer make decisions regarding their surgical options.
PRIMARY OBJECTIVES:
I. An online decision support tool will be field tested that provides patients facing a decision about contralateral prophylactic breast cancer (CPM) with evidence-based information about the expected incidence of contralateral breast cancer and the life expectancy benefit of CPM. The tool will be designed for use in clinical settings and viewed jointly by the patient and physician as part of a shared decision making process around CPM.
OUTLINE:
Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
Other: Decision Aid · Other: Questionnaire Administration
Use decision making tool
Ancillary studies
Acceptability of the decision support tool
Patients' rating of the acceptability of the decision support tool will be assessed using questions from the Ottawa Acceptability Measures, including the clarity, amount, and balance of the information provided by the tool. Acceptability data from patients enrolled in the field test will be reported descriptively.
Time frame: Up to 2 years
Changes in patient's knowledge of contralateral prophylactic mastectomy (CPM)
Will test for change in knowledge from before to after administration of the decision support tool with a breast cancer surgeon using paired samples t-tests.
Time frame: Baseline up to 2 years
Reductions in decisional conflict about CPM
Will be assessed using the Decisional Conflict Scale. Will test for reduction in decisional conflict from before to after administration of the decision support tool with a breast cancer surgeon using paired samples t-tests.
Time frame: Baseline up to 2 years
Started Apr 2017 (actual). Primary completion is estimated for Sep 2028, 137 months after the start.
Of 44 non-industry interventional studies with no phase under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 148. This study's planned 137 months is above that.
Counting every sponsor, half of 47 studies reached it within 69 months; a quarter within 30 and three quarters within 134.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Sep 2026 → Sep 2028 and completion Sep 2026 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Intraductal, Noninfiltrating →